AIDS and Cancer Virus Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, USA.
PLoS Pathog. 2010 Aug 19;6(8):e1001052. doi: 10.1371/journal.ppat.1001052.
The chronic phase of HIV infection is marked by pathological activation of the immune system, the extent of which better predicts disease progression than either plasma viral load or CD4(+) T cell count. Recently, translocation of microbial products from the gastrointestinal tract has been proposed as an underlying cause of this immune activation, based on indirect evidence including the detection of microbial products and specific immune responses in the plasma of chronically HIV-infected humans or SIV-infected Asian macaques. We analyzed tissues from SIV-infected rhesus macaques (RMs) to provide direct in situ evidence for translocation of microbial constituents from the lumen of the intestine into the lamina propria and to draining and peripheral lymph nodes and liver, accompanied by local immune responses in affected tissues. In chronically SIV-infected RMs this translocation is associated with breakdown of the integrity of the epithelial barrier of the gastrointestinal (GI) tract and apparent inability of lamina propria macrophages to effectively phagocytose translocated microbial constituents. By contrast, in the chronic phase of SIV infection in sooty mangabeys, we found no evidence of epithelial barrier breakdown, no increased microbial translocation and no pathological immune activation. Because immune activation is characteristic of the chronic phase of progressive HIV/SIV infections, these findings suggest that increased microbial translocation from the GI tract, in excess of capacity to clear the translocated microbial constituents, helps drive pathological immune activation. Novel therapeutic approaches to inhibit microbial translocation and/or attenuate chronic immune activation in HIV-infected individuals may complement treatments aimed at direct suppression of viral replication.
HIV 感染的慢性期以免疫系统的病理性激活为特征,其程度比血浆病毒载量或 CD4(+)T 细胞计数更好地预测疾病进展。最近,基于间接证据,包括在慢性 HIV 感染人类或 SIV 感染的亚洲猕猴的血浆中检测到微生物产物和特定免疫反应,提出了从胃肠道转移微生物产物是这种免疫激活的潜在原因。我们分析了 SIV 感染的恒河猴(RMs)的组织,以提供从肠道腔内向固有层和引流及外周淋巴结和肝脏转移微生物成分的直接原位证据,并伴有受影响组织中的局部免疫反应。在慢性 SIV 感染的 RMs 中,这种易位与胃肠道(GI)道上皮屏障完整性的破坏以及固有层巨噬细胞明显无法有效吞噬易位的微生物成分有关。相比之下,在黑猩猩的 SIV 感染慢性期,我们没有发现上皮屏障破坏、微生物易位增加和病理性免疫激活的证据。由于免疫激活是 HIV/SIV 感染进行性进展的慢性期的特征,这些发现表明,从胃肠道过度转移的微生物会帮助驱动病理性免疫激活,超过清除易位微生物成分的能力。抑制微生物易位和/或减轻 HIV 感染个体慢性免疫激活的新型治疗方法可能与旨在直接抑制病毒复制的治疗方法相辅相成。